While initial assumptions suggested reduced sensitivity of aFGFR3 tumors to CPIs, recent research contradicts this notion, demonstrating comparable CPI effects between aFGFR3 and intact FGFR3 (iFGFR3) BLCA cases [7, 8]. The gene discussed is FGFR3; the disease is bladder transitional cell carcinoma.